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Abstract
Background: Medication adherence to immunosuppressants in allogeneic stem cell transplantation (alloSCT) is
essential to achieve favorable clinical outcomes (e.g. control of Graft-versus-Host Disease). Over 600 apps supporting
medication adherence exist, yet they lack successful implementation and sustainable use likely because of lack of
end-user involvement and theoretical underpinnings in their development and insufficient attention to
implementation methods to support their use in real-life settings. Medication adherence has three phases: initiation,
implementation and persistence. We report the theory-driven development of an intervention module to support
medication adherence (implementation and persistence phase) in alloSCT outpatients as a first step for future
digitization and implementation in clinical setting within the SMILe project (Development, implementation and
testing of an integrated care model in allogeneic SteM cell transplantatIon faciLitated by eHealth).
Methods: We applied Michie’s Behavior Change Wheel (BCW) and the Capability-Opportunity-Motivation and Behavior
(COM-B) model using three suggested stages followed by one stage added by our team regarding preparation for
digitization of the intervention: (I) Defining the problem in behavioral terms; (II) Identifying intervention options; (III)
Identifying content and implementation options; (IV) SMILe Care Model Prototype Development. Scientific evidence, data
from a contextual analysis and patients’/caregivers’ and clinical experts’ inputs were compiled to work through these steps.
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Results: (I) Correct immunosuppressant taking and timing were defined as target behaviors. The intervention’s focus was
determined within the COM-B dimensions Capability (lack of knowledge, lack of routine), Opportunity (lack of cues,
interruptions in daily routine) and Motivation (lack of problem solving, trivialization). (II) Five intervention functions were chosen,
i.e. education, training, modelling, persuasion and enablement. (III) Twenty-four behavior change techniques were selected, e.g.,
goal setting, action planning and problem solving. (IV) Finally, seventeen user stories were developed to guide the SMILeApp’s
software development process.
Conclusion: Our example on the theory-driven development of an intervention module in alloSCT delivered by eHealth
and transplant team using a rigorous 3 + 1-stage approach based on BCW, COM-B and agile software development
techniques, can be used as methodological guidance for other eHealth intervention developers. Our approach has the
potential to enhance successful implementation and sustained use of eHealth solutions in real-life settings.
Keywords: Allogeneic hematopoietic stem cell transplantation, Medication adherence, Intervention development, Behavior
change wheel, Theory-driven, eHealth intervention, Implementation science
Background
Allogeneic stem cell transplant (alloSCT) is a well-
established, potentially curative treatment modality for
various malignant and non-malignant hematological dis-
eases in which a patient’s diseased blood-producing sys-
tem is replaced by that of a healthy person [1]. These
patients’ complex care needs demand innovation in care
delivery [2]. As information technology widely available
through smartphones has the potential to support patients
in adopting and developing essential behaviors such as
those surrounding medication adherence [2, 3], the Na-
tional Institutes of Health Hematopoietic Cell Transplant-
ation Late Effects Initiative [2] recommend that related
interventions include the support of eHealth solutions.
Medication adherence is defined as “The process by
which patients take their medications as prescribed, com-
posed of initiation, implementation and discontinuation”
(Fig. 1) ( [5], p. 697). Initiation means that the patient
starts taking a prescribed medication. Implementation
means the correspondence of a patient’s actual dosing
compared to the prescription. Implementation1 errors can
take the form of late, skipped, extra, or reduced doses or
‘drug holidays’ (skipping several doses in a row). If the pa-
tient quits the prescribed medication for any reason(s),
this is called discontinuation. The time span between the
first and last dose is called persistence [5].
Medication adherence is vital regarding clinical out-
comes in patients following alloSCT [6, 7]: as many as
80% of alloSCT patients develop an acute or chronic
Graft-versus-Host Disease (GvHD) [8, 9], a serious com-
plication in which the donor’s immune cells attack the
recipient’s body [1] leading to increased morbidity and
mortality [8–11]. Although there is limited evidence and
the few existing studies did not distinguish between the
three medication adherence phases (initiation,
implementation, persistence), we found medication ad-
herence to immunosuppressants in alloSCT essential to
prevent or treat complications such as acute and chronic
GvHD [12, 13]. The correlation is extremely compelling:
In patients without chronic GvHD only 15.6% showed
medication non-adherence to immunosuppressants
while in patients with mild GvHD already 66.7% were
non-adherent. In patients with moderate GvHD 74.1%
showed medication non-adherence and in patients with
severe GvHD even 88.9% were non-adherent [12]. As
alloSCT receive their first doses of immunosuppressants
during their hospitalization, the initiation phase of adher-
ence is not an issue [6, 7]; adherence enhancing interven-
tions need to focus on post-discharge implementation and
persistence of medication intake [12]. While available evi-
dence on medication adherence in alloSCT populations is
limited, we know that the prevalence of overall non-
adherence to immunosuppressants in adult alloSCT pa-
tients is 64.6% with 33.3% taking, 61.2% timing and 4.1%
dosing non-adherence, 3.2% drug holidays and 3.1% dis-
continuation [12].
Findings from randomized controlled trials (RCT) in other
chronic disease areas, including solid organ transplantation,
positively link behavioral interventions using eHealth with im-
provements in medication adherence [14–16], unplanned in-
patient acute care admissions [16], costs [16], general health
outcomes (e.g., blood glucose or blood pressure) [17] and
overall quality of life [16, 17]. The most successful behavior
change techniques (BCTs) (i.e., active intervention elements)
used in these trials were self-monitoring of and feedback on
medication intake [15–19], reminder cues [15, 18, 19], goal
setting, action planning and problem solving [14–17, 20]. To
date, though, no interventions focusing on these elements
have been developed and tested in alloSCT.
Moreover, compared to the wealth of findings emer-
ging from trials, comparatively little information is avail-
able on successful implementation and subsequent
evaluation of medication adherence interventions in
1Although implementation adherence uses the same word, this does
not equate with implementation in the context of implementation
science.
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general and eHealth supported behavioral interventions
in particular in real-world settings. A 2018 review on
high quality medication adherence intervention trials in
different patient populations found that most of them
did not report on essential implementation research ele-
ments, hindering the adaptation and implementation of
trial findings into real-world setting [21]. Another 2018
review paper found 681 apps to support medication ad-
herence in the Apple App and Google Play Stores [22].
However, only 84 (12.3%) of these were developed by or
in collaboration with health care professionals, only eight
(1.2%) were theory-based, and none reported patient in-
volvement in their development process [22]. And re-
gardless of whether they were developed based on a
specific theory, roughly two-thirds contained zero to two
BCTs. Of apps including BCTs, 96% included reminders
– which are often unneeded or unwanted by patients
[23]. Some higher-value BCTs such as self-monitoring
or feedback on behavior were included in a minority
(36–39%), but techniques such as social support or in-
formation about the health consequences were very rare
(1–2%) [23]. Combined with developers’ general omis-
sion of end-user involvement (especially from patients)
[22, 24], general shortages both of theoretical underpin-
nings [2, 25] and of contextual information to adapt
eHealth interventions for implementation in specific set-
tings [26–28] very likely contribute to two major con-
cerns: 1) More than two-thirds of patients who use
health-related apps abandon them within 3 months [24];
and 2) Very few health behavior support interventions
are ever successfully implemented in real-world settings
[15, 18, 19, 29–32].
In order to support post-alloSCT medication adher-
ence effectively and sustainably, eHealth supported
medication adherence interventions need to be planned
from start to finish with a clear focus on one
overarching outcome: implementation in daily clinical
alloSCT practice. Accordingly, our major goal with this
paper is to report the development of an eHealth facilitated
care medication adherence module (implementation and
persistence phase) for alloSCT. To do so, we have employed
the Behavioral Change Wheel (BCW) and the Capability-
Opportunity-Motivation and Behavior (COM-B) model –
both of which, unlike other behavioral theories (e.g. Theory
of Planned Behavior and Health Belief Model [33]), provide
multilevel perspectives and include emotional factors [34]. In
addition, we have developed user stories that facilitate the
translation of research findings first to digitalization of the
intervention, then to standard practice among both clinicians
and patients.
Methods/results
The SMILe project
This work is part of the international, interdisciplinary,
multi-phase, multicenter SMILe project, which aims at
reengineering follow-up care to patients with alloSCT
into an integrated care model first at the University
Medical Center Freiburg, Germany and in a second step
at the University Hospital of Basel, Switzerland (https://
nursing.unibas.ch/de/forschungsprojekte/forschung/for-
schung/smile/). The SMILe integrated care model builds
on the eHealth Enhanced Chronic Care Model (eCCM)
[3]. Its major aim is to introduce follow-up based on a
chronic care model by providing self-management sup-
port, optimizing delivery system design (e.g., increasing
continuity of care), clinical decision support and clinical
information systems.
As these functions involve considerable time and ex-
pertise, we recommend the introduction of a Care-
coordinator (CC) to perform them, along with the use of
a SMILe e-platform including the SMILeApp and the
SMILeCare monitoring component for the CC. For the
Fig. 1 Concept of medication adherence with initiation, implementation and persistence [4], based on [5]. From Annals of Internal Medicine, De
Geest S, Zullig LL, Dunbar-Jacob J, Helmy R, Hughes DA, Wilson IB, Vrijens B, ESPACOMP Medication Adherence Reporting Guideline (EMERGE),
169, 1, 30–35. Copyright© [2018] American College of Physicians. All Rights Reserved. Reprinted with the permission of American College of
Physicians, Inc
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first year post-alloSCT, in addition to connecting pa-
tients to the CC in the transplant center, the app will
allow patients to assess relevant biomedical and behav-
ioral parameters on a continuous basis.
Four intervention modules are integrated to support
self-management and promote alloSCT patients’ target
health behaviors: Monitoring and Follow-Up, Infection
Prevention, Physical Activity and Medication Adherence.
This paper reports on the development of the medica-
tion adherence module. This patient-centered, theory-
based development approach will increase the likelihood
of adoption and implementation in practice.
Guiding methodology
Our intervention development process used an iterative
approach applying the three stages of the BCW and one
additional stage for the SMILe Care Model Prototype
Development (Fig. 2), with each stage of execution
reviewed by the entire SMILe research team [34, 35].
The various stages and steps will be further described in
the next section (“The BCW”). Intervention develop-
ment was informed by data from our previously per-
formed multi-methods contextual analysis and evidence.
Contextual analysis refers to the mapping of relevant
multilevel contextual factors for the implementation of
an intervention, e.g. local infrastructure, leadership, mo-
tivation of the stakeholders [27]. This means the inquiry
of a specific context (in our case alloSCT follow-up care
at the University Hospital of Freiburg, Germany), prac-
tice patterns as well as the attitudes and behaviors of all
parties involved. Our preliminary work included such a
contextual analysis using a cross-sectional quantitative
survey of 60 alloSCT patients and five clinicians working
in alloSCT. That analysis also included qualitative data,
namely individual interviews with another ten alloSCT
patients and three alloSCT clinician focus groups. The
detailed description of the methods and results of this
contextual analysis were recently published elsewhere
[36]. It studied all relevant contextual aspects of the pro-
posed integrated model of care, e.g., socio-cultural as-
pects at the micro (i.e., patient) and meso (i.e.,
transplant center) levels. Further, we examined the feed-
back of 21 stem cell transplant patients and eleven care-
givers collected during three feedback rounds in
Freiburg im Breisgau (Germany). Both, allogeneic and
autologous stem cell transplant recipients were invited
to give feedback as they participated a shared self-help
group. We presented them our preliminary results and
asked them to rank e.g. the importance of barriers to
medication adherence or whether the proposed BCTs
were feasible for them. The patients’ and caregivers’
feedback was included in the further development of the
intervention. In addition, we reviewed existing evidence
on 1) definition, prevalence and consequences of medi-
cation non-adherence in alloSCT (quantitative, appendix
search diagram 1), 2) barriers and facilitators of medica-
tion adherence in alloSCT and solid organ transplant-
ation (qualitative, appendix search diagram 2), and 3)
existing interventions to support medication adherence
in alloSCT and solid organ transplantation (quantitative,
appendix search diagram 3). Because evidence in
alloSCT is very limited, but medication adherence tasks
are similar in alloSCT and solid organ transplant pa-
tients, we also included pertinent literature from solid
organ transplantation.
The BCW
One particularly rigorous and widely useful system of
developing and implementing behavior change interven-
tions is the BCW [37, 38]. Combining 19 behavior
change frameworks, the BCW is used to identify, under-
stand and explain behaviors and their influencing fac-
tors. It consists of three stages: 1) understanding the
behavior, 2) identifying intervention options and 3)
Fig. 2 The 3 stages and 8 steps of the BCW [34] with our added stage 4 (self-developed figure)
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identifying content and implementation options, which
are further divided into eight steps (Fig. 2) [34].
BCW stage 1: understand the behavior
Step 1: define the problem in behavioral terms
Before attempting to modify a behavior it is necessary to
understand it in detail and to identify possible starting
points for change [34]. Therefore, the first step of the
BCW is to define the problem in behavioral terms using
three leading questions: What is the behavior?; Where
does it occur?; and Who is involved?
In order to answer these questions, we first deepened
our understanding of the problem by performing a scop-
ing review of studies reporting definitions, prevalences
and consequences of medication non-adherence in
alloSCT (appendix, search diagram 1). From the twelve
studies we identified, we extracted information on defin-
ition and relevance of medication non-adherence.
Results. Particularly regarding immunosuppressive
regimes we found medication adherence essential in
alloSCT to prevent or treat complications such as
acute and chronic GvHD [12, 13]. However, almost
65% of participating patients struggled with medica-
tion intake, especially immunosuppressants taking and
timing (implementation phase of medication adher-
ence) [12] (Table 1).
The contextual analysis data of our preliminary work
(see Guiding methodology section) [36] indicated that
alloSCT patients were aware of the importance of fol-
lowing the medication regimen closely, especially when
family, friends and caregivers were involved in medica-
tion management. According to clinicians, medication ad-
herence was not systematically assessed at the studied
transplant center. They also acknowledged a need for a
person such as an Advanced Practice Nurse (APN) to co-
ordinate follow-up, i.e., a CC [36]. The insights obtained
from the literature review and contextual analysis enabled
us to define the problem in behavioral terms (Table 1).
BCW step 2: select target behavior
The second step is to create a list of behavioral compo-
nents known to influence the problem. From this list, be-
haviors are selected based on their expected impact (when
improved) on target outcomes, the likelihood that they
can be changed, the extent of expected spillover effects on
other health behaviors and their measurability [34].
Results. In the literature search we identified 12 quanti-
tative studies about prevalence and consequences of differ-
ent behavioral components (appendix, search diagram 1).
Based on the information from that literature review, we
compiled a list of potential target behaviors that influence
implementation and persistence adherence. For example,
taking, timing and dosing immunosuppressants correctly
(three behaviors), following food considerations concerning
immunosuppressants and not taking drug holidays (imple-
mentation dimension). From this list, we selected correct
taking and timing of immunosuppressants as the two most
Table 1 Definition of the problem in behavioral terms
Leading question Possible answer
What is the problem/
behavior?
Medication non-adherence, which is associated with poor clinical and economic outcomes [20, 39], pervades all chronic-
ally ill patient populations [12, 13, 29, 40]. Post-alloSCT patients are chronically ill. With a mean of 12 medications [41],
their medication regimen is complex. Most important medications in the 1st year post-alloSCT are immunosuppressants
and anti-infectious medications. Co-medications (e.g., antibiotics, antivirals, fungicide) are essential to prevent and treat in-
fections [42].
Using the ABC taxonomy, medication adherence consists of three interrelated phases: initiation, implementation and
persistence [5], the latter two being relevant after alloSCT. Implementation adherence includes correct taking, timing,
dosing, no drug holidays and correct food considerations (e. g., no grapefruit juice) [5, 12].
While available evidence on medication adherence in alloSCT populations is limited, we know that the prevalence of
overall non-adherence to immunosuppressants in adult alloSCT patients is 64.6%: 33.3% taking non-adherence, 61.2% tim-
ing non-adherence, 4.1% dosing non-adherence, 3.2% drug holidays and 3.1% discontinuation [12]. Non-adherence to im-
munosuppressants is strongly associated with GvHD [12]. Less is known in view of co-medication. And while only 57% of
the adult alloSCT patients report perfect medication adherence to all prescribed drugs after alloSCT [43], non-adherence
can be quite selective, e.g., in one study 17% of subjects discontinued antifungal prophylaxis prematurely [44].
Therefore, it is crucial to optimize adherence, especially to immunosuppressants, in adults after alloSCT (implementation
and persistence).
Where does it occur? After alloSCT, non-adherence occurs at the patients’ homes and / or where they are at the scheduled time of medication
intake.
Our contextual analysis showed that alloSCT patients within the target setting understood the importance of following
their medication regimen. According to clinicians, though, medication adherence was not systematically assessed at the
target transplant center. If assessed, asking the patients for intake, monitoring blood-levels or checking for rejection signs
were reported to be the most used practices. Clinicians also noted a need for a qualified person, e.g., an Advanced Prac-
tice Nurse or dedicated CC, to coordinate follow-up [36].
Who is involved?
Who is our target group?
The entire health and health-related network surrounding adult patients after alloSCT (family, friends, health care profes-
sionals, ...) [36].
Community dwelling adult post-alloSCT patients
alloSCT Allogeneic stem cell transplantation, GvHD Graft-versus-Host Disease, CC Care-coordinator
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prevalent and important target behaviors. This selection
was guided by a systematic rationale: changing these behav-
iors was expected to have the best overall combination of
direct impact on clinical outcomes, spillover effects on
other behaviors, e.g., taking no drug holidays, and ease of
measurement (Table 2). We based our rating system (i.e.,
++ very promising, + promising, ± not promising but worth
considering, − unacceptable) on evidence from the litera-
ture and the research team’s clinical expertise.
BCW step 3: specify the target behavior
As the third step is to examine the selected behaviors (in
our case, two) both from the patient’s perspective and
within the context of the surrounding system [34], we
specified each in terms of who, what, when, where, how,
how often and with whom they occurred. This choice of
details was based on previously evaluated evidence from
the literature [12, 13, 41], but mainly on our contextual
analysis [36] and our research team’s clinical expertise.
Results. The resulting details (Table 3) allowed identi-
fication of target behaviors [34].
BCW step 4: identify what needs to change
The fourth step is to identify what needs to change by
analyzing risk factors not only at the individual but also
higher in the system. For this step, the COM-B model
(Fig. 3) – the center of the BCW (Fig. 4) – supports be-
havioral analysis very well, as it acknowledges that be-
haviors such as medication non-adherence are
influenced by the physical and psychological capability,
physical and social opportunity as well as reflective and
automatic motivation. Capability is the capacity to en-
gage in a certain health behavior (e.g., medication in-
take); opportunity refers to factors external to the
individual that make behavior possible; and Motivation
refers to the brain processes – whether reflective or un-
conscious – that direct behavior. Two common examples
of capability are cognitive functionality (psychological
capability) and the physical capability to swallow medica-
tion. Opportunities may lie in the accessibility of the medi-
cation (physical opportunity) or support from a partner
(social opportunity); and motivational aspects would in-
clude attitudes about the medication, such as beliefs about
its efficacy (reflective motivation) or treatment fatigue
(automatic motivation).
Of course, capability and opportunity also affect mo-
tivation, and the behavior itself influences all three ad-
herence components (Fig. 3). As an ecologic model (i.e.,
involving factors on the patient, health care provider,
health care organization and health care system level),
the BCW is helpful in understanding behaviors’ determi-
nants and emotional drivers and provides the basis for
the following steps.
In addition, the COM-B can be combined with the
Theoretical Domains Framework (TDF) [34], which syn-
thesizes multiple behavioral theories and includes 14 do-
mains of behavioral influence (Fig. 4). Each domain
represents theoretical constructs such as knowledge,
skills or beliefs and relates to one COM-B component.
Used together, the COM-B and the TDF allow a behav-
ioral diagnosis, which facilitates the choice of effective
behavior change interventions [34].
Where exactly to initiate behavior change was deter-
mined partly by the results of the contextual analysis
and partly by qualitative evidence. We located the latter
via a scoping review for qualitative findings on alloSCT
patients’ and clinicians’ perspectives, barriers and facili-
tators to medication adherence. Due to limited evidence
Table 2 List of possible target behaviors
Possible target behavior Impact of
behavior
change
Likelihood
of change
Spillover effect Measurement
Correct taking of immunosuppressants (i.e. persistently reducing
number of missed immunosuppressants doses)
++
(↓ risk of GvHD
[12])
++ ++ (adherence to co-
medication, no drug holidays)
++ [45]
Correct timing of immunosuppressants ++?
(↓ risk of GvHD?
[46, 47])
+ ++ (adherence to co-
medication, no drug holidays)
++ [45]
Correct dosing of immunosuppressants ++
(↓ risk of GvHD
[12])
+ + (adherence to co-
medication, no drug holidays)
± [45]
Performing no drug holidays ++
(↓ risk of GvHD
[12])
++ + (adherence to co-
medication)
++ [45]
Following food considerations ++
(↓ risk of GvHD
[12])
+ + (considerations for co-
medication)
- [45]
EM Electronic monitoring; GvHD Graft-versus-Host Disease
(++ very promising) (+ promising) (± not promising but worth considering) (− unacceptable)
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in the alloSCT population we also included literature
from the solid organ transplant population (appendix,
search diagram 2).
Results. According to the findings of the 16 identified
qualitative studies and the contextual analysis, imple-
mentation of medication adherence is influenced by a
broad set of multilevel factors, which we organized
within the COM-B model (Table 4). For instance, lack of
knowledge and lack of routine (Capability), lack of cues
and interruptions in daily routine (Opportunity), lack of
problem solving, trivialization and denial (Motivation)
were identified as possible barriers to medication adher-
ence implementation.
We crosschecked and compared our review’s results
with those of two recent quantitative studies on multi-
level determinants of medication non-adherence in heart
transplantation [62]. In addition, we analyzed data from
a long-term bio-psychosocial follow-up in solid organ
transplantation [64] in which our research group was in-
volved. The results supported our previous findings.
According to the findings of the 16 identified qualitative
studies [48–61, 63, 65], the results of our contextual ana-
lysis and patient feedback, we selected the highest-priority
barriers. The behavioral diagnosis findings for each do-
main and necessary changes are listed in Table 4.
BCW stage 2: identify intervention options
BCW step 5: identify intervention functions
After identifying the target needs, the relevant interven-
tion functions (Fig. 4) must be identified. The BCW lists
nine of these (education, persuasion, incentivization, co-
ercion, training, restriction, environmental restructuring,
modeling, and enablement), each of which is a set of
effective intervention categories with the potential to
mitigate barriers to behavior change identified by the
COM-B and/or TDF models.
To guide our selection, we applied the APEASE cri-
teria (test of Affordability, Practicability, Effectiveness
and cost-effectiveness, Acceptability, Side effects/safety,
and Equity) [66] on each intervention function (Table 5).
The identified components were rated (i.e., ++ very
promising, + promising, ± not promising but worth con-
sidering, − unacceptable) with consideration for available
evidence, the research team’s clinical expertise, our con-
textual analysis and patient feedback. The APEASE cri-
teria were also applied in further steps, always using the
same data sources mentioned here. To search for exist-
ing interventions that support medication adherence in
alloSCT, we performed a systematic literature search
(appendix, search diagram 3). Due to limited evidence in
the alloSCT setting, we also included findings from the
solid organ transplant population.
Results. According to eleven quantitative studies we
identified on medication adherence-enhancing interven-
tions, combinations of education, training, enablement,
modeling, environmental restructuring and persuasion
were effective functions to support medication adher-
ence [15, 18–20]. After considering the feasibility of each
according to our contextual analysis, we excluded envir-
onmental restructuring, as this was not feasible within
the SMILe project’s context. We then presented the se-
lected functions to alloSCT patients and caregivers to
discuss their feasibility and usefulness. The research
team applied the APEASE criteria to the functions fa-
vored by the patient and caregiver group. They found
that education, training, enablement, modeling and
Table 3 Specification of target behaviors
Target behavior Correct taking of immunosuppressants Correct timing of immunosuppressants
Who Adult alloSCT patients Adult alloSCT patients
What Take immunosuppressants 2x/day Take immunosuppressants at prescribed time
When a.m. & p.m.
(at least until day 120–180, mean 16 months after alloSCT)
e.g., 900 & 2100, max. Deviation 2 h
(at least until day 120–180, mean 16months after alloSCT)
Where Patient location (home, work, vacation, ...) Patient location (home, work, vacation, ...)
How Swallowing pills with fluid (e.g., water, no grapefruit juice) Swallowing pills with some fluids (e.g., water, no grapefruit juice)
How often Every day Every day
With whom Alone (possibly with support of family/friends, nurse) Alone (possibly with support of family/friends, nurse)
alloSCT Allogeneic stem cell transplantation
Fig. 3 The COM-B framework to understand a behavior [34] (open
access figure)
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persuasion to have the greatest potential to improve
medication adherence in post-alloSCT patients (Table
5).
BCW step 6: identify policy categories
In this step, policy categories are identified (Fig. 4). The
BCW lists seven such categories (communication/mar-
keting, guidelines, fiscal measures, regulation, legislation,
environmental/social planning, service provision), from
which researchers can choose those that will best sup-
port delivery of the intervention functions selected in
step 5 [34]. We based our selection of policy categories
on the results of our contextual analysis.
Results. After applying the APEASE criteria once
again we selected two policy categories – regulation and
service provision – as those most congruent with our
chosen intervention functions (Table 6).
BCW stage 3: identify content and implementation
options
BCW step 7: identify behavioral change techniques
The seventh step is to identify BCTs, which are the ac-
tive elements of an intervention. The BCT Taxonomy
describes 93 BCTs, classified in 19 categories (e.g., goal
setting, action planning, problem solving, information
about health consequences, self−/monitoring of behavior,
self-reward, punishment) to change a behavior. Thanks
to the BCT Taxonomy, uniform terminology can also be
used to describe intervention components, allowing rep-
lication of a study [34]. Based on the findings of the
previous BCW steps and the data sources explained
above, we selected the BCTs that we judged would best
support our chosen intervention functions.
Results. In the literature search, we identified 11
quantitative studies on interventions (appendix, search
diagram 3). According to the results, cognitive-
educational interventions (e.g., information and instruc-
tions) were frequent, but showed inconsistent results in
enhancing medication adherence [18, 20]. Behavioral in-
terventions (e.g., counseling, reminders, self-monitoring
and feedback on medication intake) led to significant
improvements in medication adherence [15, 18–20].
While combinations of cognitive-educational, behavioral
and psychological-affective interventions showed the
best improvements, even these results were inconsistent
[18, 19]. To select suitable BCTs for our intervention,
we applied the APEASE criteria to those we judged most
promising (Table 7).
Based on these findings, we prepared a draft of the
intervention, i.e. visualized the selected BCTs (Table 7)
including a short description and a self-drawn represen-
tation of an app on a PowerPoint presentation. We
showed the presentation to stem cell transplant patients
and caregivers and discussed the various parts’ feasibility
and usefulness. The participants had the possibility to
vote for the different BCTs via a real-time smartphone-
based survey (using mentmeter.com) as well as via the
accompanying oral group discussion. The patients’ feed-
back indicated that they saw the intervention as both
feasible and supportive. With consideration for all of the
Fig. 4 The behavior change wheel [34] (open access figure)
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Table 4 Barriers of medication adherence sorted by COM-B
COM-B TDF What needs to happen for target behavior to
occur?
Information about barriers to
medication adherence
Do factors/barriers need to change
to perform target behavior (based
on contextual analysis)?
Physical
capability
Physical skills Being physically able to swallow pills and
remember if already taken
Emesis, nausea [48, 49] a b
Poor physical condition [50]
a b
NO Physical limitations (e.g.
cognitive function) which can’t
change
YES Limited physical stamina (e.g.
fatigue, nausea)
Psychological
capability
Knowledge Knowledge why intake and timing of
immunosuppressants is important
Lack of knowledge about
medication and
consequences [48, 50–61] a b
Wrong information b
Ambiguities / vague advise
[50, 52, 53] a
Unclear, where getting
prescription from and which
pharmacy [49–51, 57, 62] a b
YES Lack of knowledge about
importance and consequences of
medication (non-) adherence
Behavioral
regulation
Apply the knowledge of correct medication
intake and timing in every aspect, applying if-
then-rules
Development of coping strategies for barriers
Lack of routine [51, 52, 55–
57, 59, 63] a
No sense of autonomy
regarding medication intake
[51]
History of MNA [53, 64]
Longer time since
transplantation [64]
Current major life event
(other priorities) [49, 53]
Busy lifestyle [48, 49, 51, 54,
57]
Alcohol and substance abuse
[51]
YES Lack of procedural knowledge
of medication intake
YES Lack of behavioral regulation
(e.g. self-monitoring)
YES Lack of skills to develop coping
strategies facing barriers
Memory,
attention &
decision
processes
Notice and remember at prescribed time
during daily life to take medication
Information overload b
Forgetfulness [48, 49, 51, 52,
54–57, 65] a, poor executive
function after transplantation
[53, 65]
Forgetting get a new
prescription on time [49, 50,
54, 56, 57, 60] a b
YES Limitations in memory,
concentration, attention & decision
processes ⋄ Lack of awareness /
recognition in daily life
Cognitive and
inter-personal
skills
Development of habit in correct timing and
intake of medication,
Skill to ask for help if needed
Unable to cope with
changed prescription [54]
Lack of psychological skills to
fill pill boxes / prepare
medication correctly [60]
YES Lack of habit-forming, goal-
setting or action-planning skills
Physical
opportunity
Environ-
mental
context and
resources
Enough medication available, readily
accessible at opportunities, enough reminder
clues
Not having medicines when
being away from home [48,
49, 54, 57] a
Lack of cues [48–50, 52, 55–
57, 60] a b
Time of intake «does not fit»
to lifestyle [48–50, 56, 57, 65]
a
Interruptions in daily routine
[48–50, 52, 54, 56, 57] a
Distance to clinic, no regular
follow up [50]
Travelling (e. g. to other time
zone) [48, 49, 57]
Changed time of intake due
to clinical visits implies that
it is not important [56, 57] a
Complexity due to
polypharmacy [48, 50, 51, 53,
56, 61] a b
Barriers to take
immunosuppressants [62]
YES Lack of facilitation via
accessibility, possibility, easiness,
availability, convenience
YES Lack of facilitation via support
for memory, concentration, attention
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Table 4 Barriers of medication adherence sorted by COM-B (Continued)
COM-B TDF What needs to happen for target behavior to
occur?
Information about barriers to
medication adherence
Do factors/barriers need to change
to perform target behavior (based
on contextual analysis)?
Social
opportunity
Social
influence
Patient participation & empowerment
regarding an increased awareness about that
medication management is a shared duty of
everyone involved in the care
Lack of family support
(emotional, instrumental)
[48–53, 55–57, 59, 61, 62, 65]
a b
Lack of social support [48,
49, 51, 53, 55, 56, 59, 61, 62,
65] b
Lack of peer learning (blogs,
internet forum, waiting
room) [52, 53, 56, 61] a
Incorrect lay knowledge
from peers b
Lack of positive and negative
role models [58]
Lack of individual support
(by nurses, pharmacists) [50,
52, 53, 56] a
Avoiding taking medication
in public / in front of friends
[56]
Lack of comparison with
worse ill people [56, 57]
Lack of trusting partnership
with health professionals [50,
53, 57, 59]
Lack of attention from nurses
/ health care professionals
[53, 55, 62]
YES Lack of positive role models
YES Lack of social or peer support
(e.g. patient empowerment /
participation, private or, professional
support)
YES Lack of awareness that
medication intake can be improved
by of everyone involved in the care
Automatic
Motivation
Emotion Positive emotions related to medication
adherence
Feeling overwhelmed [58,
63] b
Burnout / treatment fatigue
[48, 52, 55, 57]; Depression
[51, 57, 65]
Low quality of life (direction
of association unclear) [51]
Negative emotions / attitude
[49, 53, 58, 59]; Distress [51,
54]
Desire for independence in
self-management [52, 65]
Nuisance due to repetitive
reminder [57]
Low gratitude toward
medical team/donor [48–52,
54–56, 61]
Tablet phobia (fear of
swallowing tablets) [53]a
YES Lack of coping strategies
YES Low relationship with health
care provider
YES Fear of embarrassment
Reinforcement Strategies for possible problems Incompatibility of the
immunosuppressants a b
Side effects [48–53, 65] a b
YES Lack of problem solving
strategies
Reflective
Motivation
Intentions Have willingness and a plan on correct intake
and timing
Lack of intention to adhere
[51] a
Not interested in learning
about medication before
transplant [60]
YES Insufficient intention
YES Insufficient goals
Beliefs:
consequences
Correct beliefs of resulting consequences of
non-adherence
Beliefs in illness, medication
and side effects [48, 50–61,
63] a b
Lack of knowledge about
consequences [48–55, 57, 60]
a
Consequences of MNA not
clear (health belief) [51, 55] a
b
YES False beliefs about
consequences
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information thus far compiled, we selected 24 patient-
level BCTs, including goal setting, action planning and
self-monitoring of behavior. All selected BCTs are listed
in Table 8.
BCW step 8: identify mode of delivery
The eighth and last of the BCW’s core processes is to
identify the most suitable mode of delivery for the selected
BCTs. This determines how the intervention should be
delivered to the alloSCT patients and their caregivers, i.e.,
the end-users. A wide variety of delivery modes can sup-
port an intervention’s implementation and effectiveness,
ranging face-to-face individual or group sessions to mobile
phone apps [34]. The optimal delivery mode was deter-
mined using information generated from the previous
steps, the contextual analysis and end-user feedback [34].
Results. Our contextual analysis [36] showed that
alloSCT patients were open to technological assistance
but emphasized that eHealth support should not replace
personal contact with the health care team. Accordingly,
of all available possibilities for face-to-face (delivered by
the CC) or distance (technology assisted) interventions,
we selected the most suitable mode of delivery for each
of our intervention’s BCTs (Table 8).
The resulting draft of the SMILe Care Model Prototype
integrates a CC (an APN with specialization in oncology)
and the SMILeApp (“prototype” means the whole care
model, not only the app component). The BCTs to sup-
port medication adherence will be delivered to the
patients during two face-to-face visits with the CC, e.g.
demonstration how to perform the behavior (e.g. prepare
the medication) or habit formation. Depending on the pa-
tient’s condition, the care protocols allow for a step-up ap-
proach including more intensive tailored interventions.
Between face-to-face visits, we planned to support patients
with several BCTs delivered by the SMILeApp, e.g., self-
monitoring of the behavior (Table 8).
The intervention draft was discussed with alloSCT patients
and caregivers to prioritize functionalities. This process will
later guide the order of the software and intervention develop-
ment. Patients agreed unanimously that the SMILeApp should
ideally include a current and complete medication plan that
could be automatically updated after every change to the
medication regimen. Patients considered this as a feasible way
to confirm their medication intake after every intake. Most
participants also considered it acceptable and helpful to re-
ceive a reminder for data entry once a day at a user-defined
time, with graphical feedback for entered values.
All findings arising from steps 4 to 8 are presented in Table 8
which also indicates which COM-B and TDF domains are in-
fluenced by each intervention function and policy category, as
well as the resulting BCTs and modes of delivery.
Additional stage 4: SMILe care model prototype
development
The translation of the SMILe intervention into an
eHealth solution will enable delivery of important BCTs,
e.g., self-monitoring and feedback on target behaviors to
Table 4 Barriers of medication adherence sorted by COM-B (Continued)
COM-B TDF What needs to happen for target behavior to
occur?
Information about barriers to
medication adherence
Do factors/barriers need to change
to perform target behavior (based
on contextual analysis)?
Blood test did not capture
MNA [56]
Establishing a personal
leeway of time [49]
Defining acceptable risks [52]
Trivialization and denial [52,
56, 57] a
Beliefs:
capabilities
Correct beliefs of capability in medication
management
No confidence in self-
management (mastery) [50–
53, 58]
Lack of problem solving
competence and self-efficacy
[50–52] a
YES False beliefs about own
capabilities (e.g. self-efficacy)
Goals Correct beliefs of own responsibility for
outcomes
Lack of motivation to
convalescence [55, 58] b
Making medications a low
priority [57]
YES False beliefs in own
responsibility for wanted outcomes
Optimism Confidence that desired goals will be
achieved
Maladaptive coping [65] YES Lack of adaptive coping
strategies (to reduce stress)
Role and
identity
Compatible set of behaviors with professional
identity
Evading patient hood [52]
Seeing self as a victim [52]
YES Behaviors incompatible with
professional identity
MNA Medication non-adherence
a: 10 individual interviews with alloSCT patients conducted by our research team, 2017; b: 3 focus groups with alloSCT health care providers conducted by our
research team, 2017
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patients anywhere (e.g., in their homes or workplaces) at
any time [2, 3]. Therefore, after working through the
three stages and eight core steps of the BCW, we
developed a fourth stage – SMILe Care Model Prototype
Development – which includes two steps, both of which
are based on agile software development techniques (Fig.
Table 5 Applying the APEASE criteria to select useful intervention functions
Factors/barriers that need to
change to perform target
behavior (step 4)
Intervention
function
Affordability Practicability (Cost-)
Effectiveness
Acceptability Side-
effects/
Safety
Equity Does the intervention
function meet the
APEASE criteria,
comments why yes/
no?
PhC: Lack of knowledge; lack of
awareness / recognition in daily
life
ReM: False beliefs about
consequences and own
responsibility for intended
outcomes
Education ++ ++ + ++ + + YES – provision of
knowledge
SoO: Lack of awareness that
medication intake can be
improved by everyone involved
in care
AuM: Poor relationship with
health care provider; fear of
embarrassment
ReM: False beliefs about own
capabilities; behaviors
incompatible with identity
Persuasion + + + ++ ++ ++ YES – foster positive
feelings, motivation;
beliefs about capability,
goals (self-efficacy)
Incentivization – ± – ± + ± NO – not effective and
not affordable
Coercion NO – Not acceptable
PsC: Lack of knowledge of drug
intake procedure; lack of skills to
develop coping strategies;
limitations in memory &
decision processes
PhO: Lack of facilitation via
support for memory,
concentration, attention
SoO: Lack of social or peer
support
AuM: Lack of coping strategies
ReM: Lack of adaptive coping
strategies
Training + + + + ++ ++ YES – provision of
training to prepare
medication / use pill
boxes / use reminders
/ self-monitoring
Restriction Not applicable
Environmental
restructuring
± ± ± ± + + NO – not affordable
(provision of
administration aids)
SoO: Lack of positive role
models
Modelling + + + ++ ++ ++ YES – provision of peer
learning, video
PhC: Limited physical stamina
PsC: Lack of habit-forming,
goal-setting or action-planning;
lack of behavioral regulation
PhO: Lack of facilitation via
accessibility, easiness,
availability, convenience
SoO: Lack of social or peer
support
AuM: Lack of problem-solving
strategies
ReM: Insufficient intention and
goals
Enablement + + + + ++ ++ YES – skills and
strategies to deal with
barriers (e.g., side
effects, interruptions in
daily routine)
PhC Physical Capability, PsC Psychological Capability, PhO Physical Opportunity, SoO Social Opportunity, AuM Automatic Motivation, ReM Reflective Motivation
(++ very promising) (+ promising) (± not promising but worth considering) (− unacceptable)
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2). Developed to facilitate early integration within the tar-
get setting, a highly iterative methodology and the inclu-
sion of end-user feedback in the development process
ensures the software’s usefulness to patients, caregivers
and clinicians alike [35].
Additional step 9: prepare digitalization
To prepare for digitization, step 9 deals with the formu-
lation of user stories [35]. User stories are a means to
capture requirements that should be delivered by a soft-
ware product. This makes their stories a valuable basis
for discussion between software developers and inter-
vention developers [35]. User stories are an opportunity
for researchers to provide key information to software
developers about important functionalities that are
needed in the app. They will not directly appear in the
app, only by means of the functionality implemented.
The goal of user stories it to provide key information be-
tween researchers and software developers and, thus, are
not communicated to patients.
While user stories can be structured in numerous
ways, the role-feature-reason format is most popular
[35]. This begins with a structured sentence (As a …
(person, e.g., allo-SCT patient), I want … (action, e.g.,
keep track of my medication intake), so that … (expected
outcome, e.g., I know if I take my medication correctly))
describing a possible software function. Structuring the
essential elements in a standard form eases the transla-
tion of the corresponding BCTs into the SMILeApp
[35]. The concrete realization of a user story is decided
in close consultation with the software development
team.
Results. To ensure the translation of the most effect-
ive BCTs into our eHealth component, we wrote 17 user
stories to the software developers in the role-feature-
reason format based on the previous findings (Table 9).
Following the principles of agile software development,
continuous end-user testing and user-centered design,
the needs and priorities these stories suggest will help
the designers first to develop mock-ups of new modules
for early user testing, then to ensure that later versions
of the app meet user needs as fully as possible [35]. A
separate paper will describe the development of the
technology aspects in detail (in preparation).
Additional step 10: prepare CC intervention
Based on the previous steps of the BCW, we wrote a
comprehensive intervention protocol for the interven-
tion’s face-to-face CC visits. This protocol describes
every face-to-face visit in terms of when, by whom and
to whom it should be delivered (patient ± caregiver(s)),
as well as which BCTs should be applied in what order
Table 6 Applying the APEASE criteria to select useful policy categories based on contextual analysis
Intervention
function
Policy category Affordability Practicability (Cost-
)Effectiveness
Acceptability (Side-
effects)
/ Safety
Equity Does the intervention function
meet the APEASE criteria,
comments why yes/no?
Communication/
marketing
± + ± ++ + + NO – not affordable, not suitable
in our situation
Guidelines – ± ± + ++ ++ NO – national level ➔ not
affordable in our situation
Fiscal measures – ± ± ± + ++ NO – not affordable in our
situation:
Germany: Financial burden due to
travelling to Tx center, drug usually
paid
Switzerland: Patients pay
Deductible + 10%
Education,
Persuasion,
Training,
Modeling,
Enablement
Regulation + + + + + ++ YES – center level ➔ regulation
about what, how & how long
contact with health care provider
can continue
Legislation NO – not relevant, not practicable
in our setting
Environmental/
social planning
± ± + + + ++ NO – WLAN access ➔ not
affordable in our situation
Education,
Persuasion,
Training,
Modelling,
Enablement
Service provision ++ ++ + ++ ++ ++ YES – e.g., support & checks via
phone / improvement of
performance at visits, introduction
of a CC
CC Care-coordinator
(++ very promising) (+ promising) (± not promising but worth considering) (− unacceptable)
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and which methods should be used. To ensure standard-
ized, reproducible intervention delivery, descriptions and
terminology adhered closely to the BCT taxonomy. The
intervention protocol was written in alignment with im-
plementation science lens, meaning, that the intervention
has been designed using the previously described imple-
mentation science methods (e.g. contextual analysis, stake-
holder involvement) in such a way that it can be
implemented and used in real world settings in the future.
Results. The complete protocol consisted of 70 pages
for all modules with the detailed description of the con-
tent to be used for education, training and supervision
of the CC. We also wrote a short version with 49 pages
for all modules to be used by the CC during the face-to-
face visits as a checklist.
We initially planned to implement and test the whole
medication adherence module via both, the CC (face-to-
face visits) and the SMILeApp in an RCT. However, due
to lack of time resources, the current version of the
SMILeApp does not include medication adherence sup-
port yet. For this reason, in the current RCT, which
started at the beginning of 2020 at the University
Hospital of Freiburg im Breisgau (FiB), only the face-
to-face visits of the medication adherence module are
implemented and tested. This downsized version of
the care model is called the SMILe-V1 Care Model
Prototype–FiB as it is tested at the University Hos-
pital of FiB. Our prepared user stories will be priori-
tized and translated into the next version of the
SMILeApp to be implemented and evaluated in com-
bination with the CC’s face-to-face visits in an RCT
at the University Hospital of Basel (USB). This full
version of the care model will be called the SMILe-
V2 Care Model Prototype–USB.
Table 8 The selected intervention functions, policy categories, BCT and delivery mode relating to COM-B and TDF
COM-B TDF Intervention
function
Policy
category
BCT Mode of delivery
Capability Physical Physical skills Enablement Service
provision,
Regulation
1.4. Action planning
11.1. Pharmacological
support
Face-to-face, Phone helpline, info on app
Mobile phone App (written information)/
Phone helpline with linkage to TX-Center
Psychological Knowledge
Behavioral
regulation
Memory, attention
& decision process
Cognitive &
interpersonal skill
Education
Training
Enablement
Service
provision,
Regulation
5.1. Information about health
consequences
2.7. Feedback on outcomes
of the behavior
8.3. Habit formation (at real
opportunities)
1.1. Goal setting
1.6. Discrepancy between
behavior & goal
1.2. Problem solving (incl.
Coping planning)
Face-to-face, App (written, video)
Face-to-face
Face-to-face
Face-to-face, App (goal-reminder)
Face-to-face, Phone helpline
Face-to-face, Phone helpline
Opportunity Physical Context &
resources
Training
Enablement
Service
provision,
Regulation
7.1. Prompts/cues
4.1. Instruction on how to
perform behavior
12.5. Adding objects to the
environment
App (reminder, information), Face-to-face
Face-to-face, App (video, written info)
App itself, information on App,
Face-to-face
Social Social influences Training
Modelling
Persuasion
Enablement
Service
provision,
Regulation
2.2. Feedback on behavior
2.3. Self-monitoring of
behavior
6.1. Demonstration of
behavior
3.1.-3.3. Emotional, practical
and unspecified social
support
Face-to-face, App (by mobile phone text)
App questionnaire, Face-to-face
Face-to-face, App (video)
Face-to-face
Motivation Automatic Emotion
Reinforcement
Persuasion
Enablement
Training
Service
provision,
Regulation
15.3. Focus on past success
8.1. Behavioral practice /
rehearsal
15.4. Self-talk
Face-to-face, Phone helpline
Face-to-face
Face-to-face, App (included in
reminder)
Reflective Intentions
Beliefs
Goals
Optimism
Role & identity
Education
Persuasion
Enablement
Training
Service
provision,
Regulation
9.1. Credible source
16.2. Imaginary reward
9.2. Pros & Cons
15.1. Verbal persuasion about
capability
App (video)
Face-to-face, Phone helpline
Face-to-face
Face-to-face, Phone helpline
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Discussion
To our knowledge, this paper is the first to provide an
example of how to develop a theory-based medication
adherence intervention for translation into an eHealth
system. Our work, embedded in an implementation sci-
ence approach, applied the principles recommended by
the BCW, and particularly of the COM-B model at its
center. This framework’s major strengths are its
Table 9 User stories according to the BCT
BCT Description User stories
1.1. Goal setting
(behavior)
Goals will be set together with patient to take the medication
correctly with a deviation < 2 h.
As a patient I want to be reminded of my set goals (which
were set during visit) on a self-determined interval (e.g. daily
/ once a week) so that I am aware of my goal and know
what to target at.
1.4. Actionplanning Patients will be encouraged to prepare a plan how to deal with
barriers (e.g. have a travel set of their medication prepared and to
take it with them when leaving home).
As a patient I want to have reliable information how to plan
my expected actions (e.g. leaving home, travelling, eating
outside) so that I do not forget the necessary preparations.
2.3. Self-monitoring
of behavior
Instructions on checking the medication plan daily and
confirming medication intake daily.
Instructions on how to control this monitoring on their own.
As a patient I want to self-monitor whether I take my medi-
cation as prescribed so that I know whether I take the drugs
correctly.
2.2. Feedback on
behavior
Give patients feedback about on how many days they correctly
managed their medication intake.
Give patients feedback about on how many days their time of
medication intake was correct.
As a patient I want to get feedback whether I take my
medication sufficiently as prescribed so that I can be sure
that I take the medication correctly
4.1. Instruction on
how to perform
behavior
Training on how to read the medication plan and prepare their
medication correctly accordingly.
As a patient I want to know how to prepare my medication
so that I can do it on my own correctly
5.1. Information
about health
consequences
Oral and written information about effects, side-effects of
medication.
Oral and written information about consequences of non
−/adherence.
As a patient I want to find information on what my
medication is for and will happen, if I do (not) take it as
prescribed (incl. wrong time) so that I know the importance
of doing it correctly.
6.1. Demonstration
of behavior
Demonstrate how to read medication plan and prepare the
medication.
As a patient I want to get explained how to use the
electronic medication plan so I can check when I have
forgotten.
7.1. Electronic
prompts/cues
Storage of medication in clear visible places (e.g., next to the
coffee machine, TV), to prompt medication intake.
Use of an electronic reminder (for medication intake, goal) on the
App with a preferred signal (e.g., alarm tone, picture).
As a patient I want to get a reminder when I need to take
my medication and don’t forget to take it.
As a patient I want to customize my app (e.g. different
tones, signals, colours, pictures) so that I connect
medication intake with a positive feeling.
1.2. Problem
solving
Identify together with patient what could be barriers to take the
medication correctly, and discuss ways in which they could help
overcome them.
Learn about most common side-effects and fitting interventions
to take.
As a patient I want to have the opportunity to call a
qualified health care provider if there are unexpected
barriers (which were not discussed face-to-face) so that I
get support in challenging situations.
As a patient I want to be able to signal the CC that she/he
should call back when she/he has time so that I get help
without disturbing the CC in an unsuitable situation.
1.6. Discrepancy
between behavior
& goal
Point out if the recorded number / time of medication intake
does not fit to the goal set.
As a patient I want to get a signal if the recorded number /
time of medication intake does not fit to the goal set so
that I realize that I have to change my behavior.
7.1. Electronic
prompts/cues
Medication plan in app As a patient I want to have my medication plan in the app
so that I can look up my medication on my smartphone.
As a patient I want to be able to update the medication
plan in the app when the prescription of physician changes
so that I have a current medication plan on my
smartphone.
9.1. Message given
by followed person
Present a speech / statement / message given by followed
patients or recognized transplant professional to emphasize the
importance of taking the medication correctly at the correct time.
As a patient I want to learn from a qualified health care
provider or a peer why the medication intake and timing is
so important so that I am aware of its importance.
15.1. Written
persuasion about
capability
Motivation when confirming medication intake / closing the app
/ pop-up
As a patient I want to get a motivational feedback that I
can successfully perform the behavior so that I feel capable
to manage the correct medication intake.
15.3. Focus on past
success
Explore with patients difficult circumstances in which patients
nevertheless managed medication intake.
As a patient I want to be able to record occasions with
correct medication intake in the App so that I feel confident
to be successful again.
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multilevel perspective and the explicit inclusion of emo-
tional factors, which tend to be less prominent or absent
in other behavioral theories [34]. While other authors
have used the BCW to develop eHealth facilitated behav-
ior change interventions, none have described their de-
velopment process (including the translation of an
intervention into an eHealth application) in this detail,
and many have not included patients or incorporated
them only at a late stage of intervention development
[37, 38, 67].
Worldwide, health care services and providers are moving
in the direction of digitization [68]. The number of newly
released health related apps is currently growing by over
200 per day: between 2015 and 2018, the number available
in the top app stores almost doubled to nearly 320′000
[24]. Many aim to support patients in medication adher-
ence [22] and some have showed promising results in RCTs
in various populations [14, 16, 17]. In the development of
an eHealth facilitated intervention, it is crucial to rely on
the theory, consider the most recent evidence, integrate in-
formation on the context where the intervention or app will
be applied and involve all major stakeholders – especially
patients – from the earliest stages [24, 28, 69, 70]. And
while theory-based interventions are most likely to improve
medication adherence [28, 69], extremely few apps are de-
veloped following these recommendations.
To exacerbate the problem, producers typically supply
limited or no information on the processes either of their
apps’ implementation or of their results in real-life settings
[16, 29]. This paper addresses these shortcomings using
the example of the SMILe integrated care model’s medica-
tion adherence intervention module. Unlike many existing
eHealth tools, our intervention development incorporated
extensive end-user involvement (i.e., of patients, care-
givers, clinicians), enhancing its relevance regarding im-
plementation in real-life settings. Our goal was not simple
to develop the best possible intervention to provide the
basis for digitalization and medication adherence interven-
tional components, but also to maximize the likelihood of
its successful implementation and sustainability in daily
clinical alloSCT follow-up care.
This paper also presents a first step towards bridging
the gap between trial and real-world contexts in the devel-
opment and implementation of a medication adherence
module: it describes how to combine empirical evidence
with contextual data [36] as the foundation of an eHealth
facilitated intervention. The involvement of all relevant
stakeholders was indispensible for this module’s durable
implementation into clinical practice [27, 34].
In addition, by developing user stories based on end-
user needs and feedback, we combined the central prin-
ciples of Implementation Science – sensitivity to
context, building on an existing evidence base, extensive
stakeholder involvement – with the principles of agile
software development and user-centered design [35, 70].
With the result – an iterative, incremental, user-
centered approach with early connection to the target
context – we intend to speed the translation of cutting-
edge research findings into routine use not only by clini-
cians but also by the target (alloSCT patient) population
[24, 70]. By involving the various stakeholder groups at
each appropriate stage, we ensured that the intervention
would fit the needs of end-users and be feasible for sus-
tainable use in clinical practice. This fact alone sets our
eHealth tools apart from others, the vast majority of
which are typically developed by software designers with
little or no input from health care research teams [24].
The BCW is a relatively novel multilevel behavioral
framework that both explains and provides a stable
framework for intervention development. Building for
our work upon the evaluation of correlates/determinants
of medication adherence intervention development, not
only does it include cognitive patient-level factors, it also
explicitly includes emotional factors that are not prom-
inent in currently prevalent health behavior models, e.g.,
the Integrated Model of Behavioral prediction [34, 71].
By assisting in the selection of appropriate behavior
change interventions [34], the BCW provides invaluable
guidance for intervention development. And by drawing
from diverse information sources it allows the combin-
ation of quantitative and qualitative evidence, the results
of contextual analysis and stakeholder involvement [34],
and the researchers’ clinical expertise. The full range of
these sources informed our intervention development.
Integral to the BCW, the BCT taxonomy [72] provides
standardized language to label even the smallest units of
behavioral change interventions. In addition to enhan-
cing the reporting and communication of complex inter-
ventions’ content and enhancing their replicability, this
level of standardization facilitates meta-analysis, espe-
cially as it is used to detect the best-performing inter-
vention components.
Although the BCW is arguably an excellent foundation
for intervention development, we added one stage to it at
the end of our development process. To speed and sim-
plify translation of the medication adherence module into
an eHealth application, we recommend and describe the
formulation of user stories as a bridge between interven-
tion developers and software developers. Congruent with
the BCW’s aims, agile software development focuses both
on stakeholder involvement and on the adaption of the
software according to the needs of its end-users [35].
One notable challenge regarding the use of the BCW
is that, even while its developers provide a step-by-step
process for intervention development, they tend to pro-
vide only brief descriptions of the links between those
steps, which can make following their recommendations
rather challenging especially for those who use the
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framework for the first time. Regarding applying COM-
B to our specific research question, we faced the issue
that there is very few evidence regarding medication ad-
herence in alloSCT. Therefore, we had to expand our
searches on similar populations. Additionally, following
the steps left us with more potential options (i.e., BCTs)
than could possibly be realized from a resource and lo-
gistical perspective. Future refinement of the BCW could
help to overcome this challenge by providing more guid-
ance on which of the possible BCTs would be most ap-
propriate. In our example we based the selection and
reduction to the most important and promising options
on the feedback of the stakeholders to promote feasible
implementation: We applied the APEASE criteria to each
possible BCT and discussed which possible app function-
alities would specifically help stem cell transplant patients
and their caregivers with decision-making and
prioritization. This approach ensured that the intervention
would fit the needs and preferences of the end-users.
Application of theory is facilitated by examples. While
our example focuses directly on the development of be-
havioral intervention and eHealth app, it and its under-
lying theory can also be applied to the adaptation of
existing interventions and apps to new contexts. Never-
theless, a strong knowledge of the theory is crucial and
needs to be firmly in place before starting the develop-
ment process. To bring all the needed competencies and
perspectives to the table, an interdisciplinary team and
stakeholder involvement are essential.
Our international multidisciplinary research team con-
sists of 31 researchers and clinicians, two of whom were
members of the BCW development team for the medica-
tion adherence module. Several of our researchers also
went to London to follow summer courses offered by
the group led by Susan Michie, who developed the
BCW. In all, development of the SMILe intervention
modules required an investment of more than 1 year.
Therefore, we advise other researchers that, to prepare
adequately for this task, they should combine readings of
papers and books with formal training. Another valuable
option would be to collaborate with more experienced
researchers to peer support this process.
It is still unknown, whether a theory-based developed
intervention module such as ours is able to improve
medication adherence in alloSCT. In addition, it is un-
clear whether an analogue or digital intervention, or
even the combination of both is the most successful
which needs further investigation. Our study’s results
will support agile technology development of the SMILe
medication adherence module as part of the SMILe inte-
grated care model. The SMILe-V1 Care Model Proto-
type–FiB (without medication adherence in the
SMILeApp) and SMILe-V2 Care Model Prototype–USB
(with medication adherence in the SMILeApp) will
subsequently be implemented and tested as part of an
implementation science study to address these know-
ledge gaps (https://smile.nursing.unibas.ch/). Once the
SMILe Care Model Prototype has proven its effective-
ness, it can be sustainably implemented in clinical prac-
tice as it was developed under consideration of
implementation science aspects (e.g. feasibility and
acceptability).
Limitations
Our development of the eHealth component of our care
model was subject to certain restrictions. For example,
as contextual factors such as data security legislation are
very strict in Switzerland and the EU, certain proposed
app functions could not be included. Even if qualitative
literature and the involved patients had certain priorities
regarding the functionality of the SMILeApp, other fac-
tors such as the legal framework could force different se-
quences of the app development process. However, the
whole medication adherence module is more than just
the eHealth part, why a first testing of the intervention
is still possible.
Conclusion
As intended, this paper describes the theory-driven de-
velopment, based on the BCW, of a medication adher-
ence intervention module as part of the SMILe
integrated care model for alloSCT patients, which in-
cludes a patient-centered app and introduces one new
care team role: a CC. The associated study’s results are
currently in use for agile technology development,
employing a user-centered design approach, of the in-
novative SMILe integrated care model’s medication ad-
herence module. The overall care model will be
implemented and tested as part of a planned implemen-
tation science study. While the methods described are
applied to this particular medication adherence interven-
tion, as they follow BCW recommendations, they can be
adapted to the development of a wide range of behavior-
targeted eHealth applications.
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